Clinical Trial Update: Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge [Phase 1]

View source ↗

Summary

Phase 1 trial assessing a pDNA CMV vaccine (VCL-CT02) followed by a Towne CMV vaccine challenge for Cytomegalovirus infection; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Towne CMV Vaccine (cytomegalovirus vaccine (Towne strain))
• VCL-CT02

Snippet

Sponsor: University of California, San Francisco | Conditions: Cytomegalovirus Infection | Phase 1 | Status: COMPLETED